Ryaltris, a nasal spray used for allergic rhinitis, has been discontinued in the United States. The manufacturer, OptiNose, announced the decision in early 2024, citing commercial reasons for the withdrawal from the U.S. market [1].
What caused Ryaltris to be discontinued?
The discontinuation of Ryaltris in the U.S. was a strategic business decision by OptiNose, the developer. The company stated that the decision was based on commercial considerations and is not related to safety or efficacy issues with the drug itself [1].
When did Ryaltris stop being available?
Following the announcement in early 2024, Ryaltris is no longer available for prescription in the United States. Patients seeking this medication will need to consult with their healthcare provider for alternative treatment options [1].
What are the alternatives to Ryaltris for allergy treatment?
For individuals who were using Ryaltris for allergic rhinitis, several alternative treatment categories exist. These include other nasal steroid sprays, oral antihistamines, decongestants, and leukotriene modifiers. The most suitable alternative will depend on an individual's specific symptoms and medical history, and should be discussed with a healthcare professional [2].
How do other nasal allergy sprays compare to Ryaltris?
Ryaltris combined olopatadine, an antihistamine, and mometasone furoate, a corticosteroid, delivered via OptiNose's Breath-Powered device. Other nasal allergy sprays may contain a single active ingredient, such as a corticosteroid (e.g., fluticasone, mometasone, budesonide) or an antihistamine (e.g., azelastine), or different combinations. The efficacy and side effect profiles can vary among these different formulations and delivery systems [2].
What was the patent situation for Ryaltris?
While specific patent expiry dates are not publicly detailed in the provided information, patent protection is a standard consideration for pharmaceutical products. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can include details on patent expiry and any associated exclusivity periods [3].
Were there any other markets where Ryaltris was available?
The discontinuation specifically pertains to the U.S. market. Information regarding the availability of Ryaltris in other countries was not provided.
Sources:
1. https://www.optinose.com/
2. https://www.mayoclinic.org/diseases-conditions/allergies/diagnosis-treatment/drc-20351141
3. https://drugpatentwatch.com/